SECURITIES AND EXCHANGE COMMISSION

                                             WASHINGTON, D.C. 20549

                                                   FORM 10-QSB


[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934
         For the quarterly period ended September 30, 2000

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)  OF THE
         SECURITIES EXCHANGE ACT OF 1934 for the transition period from
         __________________ to __________________

         Commission File Number 0-23957
         CIK 0001058549

                                 MEDITECNIC, INC.
                  (Exact Name of Registrant as specified in its Charter)

            Delaware                               87-0430532
(State or other Jurisdiction of                       I.R.S. Employer Identi-
Incorporation or Organization                             fication No.)

  24351 Pasto Road, Suite B, Dana Point, California 92629
(Address of Principal Executive Offices)                    (Zip Code)

                           (949) 489-2400
                     (Registrant's Telephone Number, including Area Code)


         Indicate by check mark whether the Registrant (i) has filed all reports
 required to be filed by Section 13, or 15(d) of the Securities Exchange Act of
 1934 during the preceding 12 months (of for such shorter period that the
Registrant was required to file such reports) and (ii)
has been subject to such filing requirements for the past 90 days.

                                          Yes    X           No

         Indicate the number of shares outstanding of each of the issuer's
classes of Common Stock, as of the latest practicable date.

Common Stock, $.001 par value                      7,527,545
Title of Class                                    Number of Shares outstanding
                                                        at September 30, 2000
No exhibits included.

                                                        1
<PAGE>

                                                            MEDITECNIC, INC.
                                         (A Company in the Development Stage)

                                                             BALANCE SHEETS



                                                                 ASSETS
<TABLE>
<CAPTION>

                                                                                        December 31,      September 30,
                                                                                            1999              2000


Current Assets
<S>                                                                                           <C>               <C>
      Cash and Cash Equivalents                                                               267,820           868,757
      Interest Receivable                                                                       9,597            10,499
      Marketable Securities                                                                 1,657,600           749,210


      Total Current Assets                                                                  1,935,017         1,628,466

Other Assets - Patents                                                                        637,260           697,650
      Note Receivable - non current                                                           134,093           276,887
      Deposits                                                                                234,066           296,896

      TOTAL ASSETS                                                                     $    2,943,486   $     2,899,899





                                                  LIABILITIES AND STOCKHOLDERS' EQUITY



STOCKHOLDERS' EQUITY
Preferred Stock, $.001 par value; 1,000,000 shares
  authorized; 1,000 shares of Series A Preferred
  Stock issued and outstanding                                                                      1                 1

Common Stock, $.001 par value; 20,000,000 shares
  authorized; 7,527,485 shares issued
  and outstanding                                                                               7,528             7,528

Additional paid-in Capital                                                                  3,075,055         3,075,055

Accumulated deficit during the development stage                                            (148,655)         (185,356)
Accumulated other comprehensive income                                                          6,507             2,671




      TOTAL STOCKHOLDERS' EQUITY                                                            2,943,486         2,899,899





TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY                                             $    2,943,486   $     2,899,899


</TABLE>


     The accompanying notes are an integral part of the financial statements.

                                                                   2
<PAGE>

                                                            MEDITECNIC, INC.
                                       (A Company in the Development Stage)

                                                        STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>



                                                                                                                       CUMULATIVE
                                                FOR THE NINE MONTHS                     FOR THE THREE                     FROM
                                                       ENDED                            MONTHS ENDED                 March 24, 1998
                                                   September 30,                        September 30,                      TO
                                              2000             1999               2000              1999        September 30, 2000

<S>                                     <C>         <C>   <C>         <C>   <C>           <C>     <C>        <C>      <C>       <C>

REVENUES                                $          -0-    $          -0-    $            -0-      $         -0-       $        -0-


OPERATING EXPENSES

  General and Administrative                    24,143            21,732               8,562             16,451              101,697
  Research and Development                      13,047           204,513               4,971             28,282             246,613
TOTAL OPERATING EXPENSES                      (37,190)           226,245            (13,533)             44,733              348,314

Net Operating Income                          (37,190)         (226,245)            (13,533)           (44,733)            (348,314)

OTHER INCOME (LOSS)
  Interest Income                                8,309            20,456               1,984              7,860               38,395
  Interest Expense                               (883)           (4,772)                (17)                (9)              (7,961)
  Marketable Securities Gains (Losses)         (6,933)            19,693            (53,983)                830
                                                                                                                             132,552

    Total Other Income                             489            35,377            (52,016)              8,681              162,986

NET (LOSS)                              $     (36,701)         (190,868)            (65,549)           (36,052)            (185,328)

NET (LOSS) PER SHARE                    $        (Nil)    $        (.03)    $          (Nil)      $       (Nil)




WEIGHTED AVERAGE NUMBER
 OF SHARES OUTSTANDING                       7,527,485         7,527,485           7,527,485          7,527,485

</TABLE>



                               See accompanying Notes to Financial Statements.

                                                                   3
<PAGE>

                                                            MEDITECNIC, INC.
                                         (A Company in the Development Stage)

                                                        STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>

                                                                                                                       CUMULATIVE
                                                FOR THE NINE MONTHS                     FOR THE THREE                     FROM
                                                       ENDED                            MONTHS ENDED                 March 24, 1998
                                                   September 30,                        September 30,                      TO
                                              2000             1999               2000                1999       September 30, 2000



CASH FLOWS FROM OPERATING
ACTIVITIES

<S>                                     <C>               <C>               <C>                   <C>                 <C>
  Net (Loss)                            $     (36,701)    $    (190,868)    $       (65,549)      $    (36,052)       $    (185,328)

  Increase - Interest Receivable                 (902)           (3,302)             (1,984)            (6,184)             (10,499)
  Increase in other comprehensive
      Income (Loss)                            (3,836)               888               (476)                                   2,671



  Net cash flows from operating
   activities                                 (41,439)         (193,282)            (68,009)           (42,236)            (193,156)

CASH FLOWS FROM INVESTING ACTIVITIES
  Cash used for Patent Acquisition            (60,390)                             (637,260)                               (697,650)
  Increase in Marketable Securities            908,390          (19,693)             955,440              (830)            (749,210)
  Increase in Note Receivable                (142,794)         (136,943)            (59,470)            (1,677)            (276,887)


                                               642,376         (156,636)             895,970            (2,507)          (2,020,643)

CASH FLOWS FROM FINANCING
  ACTIVITIES
   Sale of Common Stock                                                                                                    3,082,556


  Net Cash flows from financing
   activities                                                                                                              3,082,556

NET INCREASE (DECREASE) IN CASH         600,937           (349,918)         827,961               (44,743)            868,757

CASH BALANCE AT BEGINNING
  OF PERIOD                                    267,820           860,288              40,796            555,113



CASH BALANCE AT END OF
  PERIOD                                $      868,757    $      510,370    $        868,757      $     510,370       $      868,757



Supplemental Cash Flow Information
  Cash Paid for
    Interest                                       887             4,772                  17                  9                7,961

Cash used for deposits                        (62,830)                                                                     (296,896)

</TABLE>



                               See accompanying Notes to Financial Statements.

                                                                   4
<PAGE>

                                                 MEDITECNIC, INC.
                                       (A Company in the Development Stage)

                                      NOTES TO CONDENSED FINANCIAL STATEMENTS
                                                    (UNAUDITED)
                                                September 30, 2000


1.       Comments

         The accompanying financial statements are unaudited, but in the opinion
 of the management of the Company, contain all adjustments, consisting of only
 normal recurring accruals, necessary to present fairly the financial position
at September 30, 2000, the results of operations for the three and nine months
 ended September 30, 2000 and 1999, and the cash flows for the three and nine
months ended September 30, 2000 and 1999.

         Reference is made to the Company's Form 10-KSB.  The results of
operations for the three and nine months ended September 30, 2000 are not
necessarily indicative of the results of operations to be expected for the
         full fiscal year ending December 31, 2000.

Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
 FINANCIAL CONDITION

         The Company has limited working capital and no activities.


                                            PART II.  OTHER INFORMATION

Item 1.  LEGAL PROCEEDINGS  -  None

Item 2.  CHANGES IN SECURITIES - None

Item 3.  DEFAULTS UPON SENIOR SECURITIES - None

Item 4.  SUBMISSION OF MATTER TO A VOTE OF SECURITY HOLDERS - None

Item 5.  OTHER INFORMATION - None

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

         Exhibits--None

         Reports on Form 8-K--None.


                                                         5
<PAGE>

                                                    SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
 Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                                              MEDITECNIC, INC.



Date:     October 2, 2000            By:
                                                Pierre Chamay
                                                President and Chief Financial
                                             Officer (chief financial officer
                                              and accounting officer and duly
                                                        authorized officer)


                                                         6
<PAGE>